<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04957329</url>
  </required_header>
  <id_info>
    <org_study_id>WP3</org_study_id>
    <secondary_id>2019-001642-18</secondary_id>
    <nct_id>NCT04957329</nct_id>
  </id_info>
  <brief_title>Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells</brief_title>
  <official_title>Department of Ophthalmology, Rigshospitalet-Glostrup Valdemar Hansens Vej 13, 2600 Glostrup, Denmark</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratoires Thea</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      a randomized, investigator-blind, interventinal study will compare the effect of&#xD;
      benzalkonium-chloride (BAK) preserved and preservative-free (PF) eye drops on conjunctival&#xD;
      goblet cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will conduct a randomized, investigator-blind, interventinal study on 28&#xD;
      subjects. Each subject will apply a benzalkonium-chloride (BAK) preserved eye drop (Xalatan)&#xD;
      in one eye and a preservative-free (PF) eye drop (Monoprost) in the other for 3 months. Which&#xD;
      eye gets which treatment is randomized. Before and after treatment a conjunctival print will&#xD;
      be made and the effect of the eye drops on goblet cell density will be evaluated along with&#xD;
      effect on the intraocular pressure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>each subject will be treated with a BAK-preserved eye drop in one eye and PF-eye drops in the other eye for 3 months.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular Pressure</measure>
    <time_frame>3 months</time_frame>
    <description>Change in intraocular pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Goblet cell density</measure>
    <time_frame>3 months</time_frame>
    <description>change in goblet cell density</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular surface</measure>
    <time_frame>3 months</time_frame>
    <description>change in oxford scheme grading</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucin content in tear film</measure>
    <time_frame>3 months</time_frame>
    <description>change in mucin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines in tear film</measure>
    <time_frame>3 months</time_frame>
    <description>change in concentration of detectable interleukins e.g. interleukin 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular surface disease index evaluation</measure>
    <time_frame>3 months</time_frame>
    <description>Change in OSDI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>BAK-preserved</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xalatan eye drop</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preservative-free</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Monoprost eye drop</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xalatan</intervention_name>
    <description>Eye drop</description>
    <arm_group_label>BAK-preserved</arm_group_label>
    <other_name>BAK-preserved latanoprost</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monoprost</intervention_name>
    <description>Eye drop</description>
    <arm_group_label>Preservative-free</arm_group_label>
    <other_name>Preservative-free latanoprost</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;18years&#xD;
&#xD;
          2. Danish speaking&#xD;
&#xD;
          3. Open angle glaucoma or ocular hypertension&#xD;
&#xD;
          4. Average intraocular pressure equal to or above 22 mmHg based on 3 measurements on each&#xD;
             eye&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. history of significant eye diseae (including okular trauma) other than open angle&#xD;
             glaucoma and ocular hypertension&#xD;
&#xD;
          2. Pressure difference equal to or above 4 mmHg between eyes&#xD;
&#xD;
          3. corneal thickness &lt;450μm or &gt;600μm&#xD;
&#xD;
          4. treatment with steroids within the last 3 months from inclusion&#xD;
&#xD;
          5. Significant untreated systemic disease such as hypertension, heart failure, diabetes&#xD;
             mellitus, stroke, lung disease and autoimmune diseases. Diseases are not reason for&#xD;
             exclusion if they are well treated or does not need treatment&#xD;
&#xD;
          6. smoker at inclusion&#xD;
&#xD;
          7. pregnant or breast feeding&#xD;
&#xD;
          8. women using unsafe anticonception&#xD;
&#xD;
          9. allergy towards trial medication&#xD;
&#xD;
         10. patients who cannot cooperate in eye examination&#xD;
&#xD;
         11. ocular surface defects&#xD;
&#xD;
         12. need for polytherapy in glaucoma treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miriam Kolko, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of ophthalmology, rigshospitalet-Glostrup</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Nagstrup, MD</last_name>
    <phone>+4522334504</phone>
    <email>anne.hedengran.nagstrup@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miriam Kolko, MD, PhD</last_name>
    <email>miriamk@sund.ku.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of ophthalmology, rigshospitalet.glostrup</name>
      <address>
        <city>Glostrup</city>
        <state>Danmark</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne Nagstrup, MD</last_name>
      <phone>22334504</phone>
      <email>anne.hedengran.nagstrup@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Miriam Kolko, MD, Phd</last_name>
      <email>miriamk@sund.ku.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Miriam Kolko</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Nagstrup</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of drug design and pharmacology, University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne Nagstrup, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Miriam Kolko, MD, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Miriam Kolko, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Nafstrup, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>June 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Anne Hedengran Nagstrup</investigator_full_name>
    <investigator_title>Department of ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

